Published: March 2021 | Report Code: LS12164 | Available Format: PDF | Pages: 203
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Type
1.3.2 Market Segmentation by Application
1.3.3 Market Segmentation by Route of Administration
1.3.4 Market Segmentation by Distribution Channel
1.3.5 Market Segmentation by Region
1.3.6 Analysis Period
1.3.7 Market Data Reporting Unit
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Market Definition
4.1.1 By Type
4.1.1.1 Simple
4.1.1.2 Super
4.1.1.3 Biosimilars
4.1.2 By Application
4.1.2.1 Neurological diseases
4.1.2.2 Cardiological diseases
4.1.2.3 Metabolic diseases
4.1.2.4 Infectious diseases
4.1.2.5 Orthopedic diseases
4.1.2.6 Respiratory diseases
4.1.2.7 Genitourinary/hormonal diseases
4.1.2.8 Others
4.1.3 By Route of Administration
4.1.3.1 Oral
4.1.3.2 Injection
4.1.3.3 Cutaneous
4.1.3.4 Mucosal
4.1.3.5 Inhalation
4.1.3.6 Others
4.1.4 By Distribution Channel
4.1.4.1 Indirect
4.1.4.2 Direct
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Shift in preference toward generic drugs
4.2.1.2 Increasing product launches
4.2.1.3 Rising number of collaborations and partnerships
4.2.1.4 Increasing number of mergers and acquisitions
4.2.2 Drivers
4.2.2.1 Increasing ageing population
4.2.2.2 Patent expiration of blockbuster drugs
4.2.2.3 Growing prevalence of acute and chronic diseases
4.2.2.4 Rising R&D expenditure of biotech and pharma companies
4.2.2.5 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 High marketing of branded drugs overshadows generics
4.2.3.2 Preference of physicians toward branded drugs
4.2.3.3 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Supportive regulations for generics
4.3 Impact of COVID-19
4.3.1 Supply Side Analysis
4.3.1.1 Current scenario of major manufactures and exporters of generic products
4.3.1.2 Situation of lockdown and workforce availability
4.3.1.3 Production scenario
4.3.1.4 Situation of major countries supplying generic drugs
4.3.2 Demand Side Analysis
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers
4.4.2 Bargaining Power of Suppliers
4.4.3 Intensity of Rivalry
4.4.4 Threat of New Entrants
4.4.5 Threat of Substitutes
Chapter 5. Global Market Size and Forecast
5.1 By Type
5.2 By Application
5.3 By Route of Administration
5.4 By Distribution Channel
5.5 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Type
6.2 By Application
6.3 By Route of Administration
6.4 By Distribution Channel
6.5 By Country
Chapter 7. Europe Market Size and Forecast
7.1 By Type
7.2 By Application
7.3 By Route of Administration
7.4 By Distribution Channel
7.5 By Country
Chapter 8. APAC Market Size and Forecast
8.1 By Type
8.2 By Application
8.3 By Route of Administration
8.4 By Distribution Channel
8.5 By Country
Chapter 9. LATAM Market Size and Forecast
9.1 By Type
9.2 By Application
9.3 By Route of Administration
9.4 By Distribution Channel
9.5 By Country
Chapter 10. MEA Market Size and Forecast
10.1 By Type
10.2 By Application
10.3 By Route of Administration
10.4 By Distribution Channel
10.5 By Country
Chapter 11. Competitive Landscape
11.1 Strategic Developments of Key Players
11.1.1 Product Launches and Approvals
11.1.2 Partnerships
11.2 Major Players and Their Offerings
Chapter 12. Company Profiles
12.1 Cipla Ltd.
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
12.2 Dr. Reddy’s Laboratories Ltd.
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.2.3 Key Financial Summary
12.3 Alkem Laboratories Limited
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
12.4 Teva Pharmaceutical Industries Limited
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.4.3 Key Financial Summary
12.5 Mylan N.V.
12.5.1 Business Overview
12.5.2 Product and Service Offerings
12.5.3 Key Financial Summary
12.6 Lupin Limited
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.3 Key Financial Summary
12.7 Endo International plc
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
12.8 Aurobindo Pharma Limited
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
12.9 STADA Arzneimittel AG
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.3 Key Financial Summary
12.10 Hikma Pharmaceuticals plc
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
12.11 Sawai Pharmaceutical Co. Ltd.
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.3 Key Financial Summary
12.12 Piramal Enterprises Ltd.
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.3 Key Financial Summary
12.13 Mallinckrodt plc
12.13.1 Business Overview
12.13.2 Product and Service Offerings
12.13.3 Key Financial Summary
12.14 Torrent Pharmaceuticals Ltd.
12.14.1 Business Overview
12.14.2 Product and Service Offerings
12.14.3 Key Financial Summary
12.15 Amneal Pharmaceuticals Inc.
12.15.1 Business Overview
12.15.2 Product and Service Offerings
12.15.3 Key Financial Summary
12.16 Taro Pharmaceutical Industries Ltd.
12.16.1 Business Overview
12.16.2 Product and Service Offerings
12.16.3 Key Financial Summary
12.17 Perrigo Company plc
12.17.1 Business Overview
12.17.2 Product and Service Offerings
12.17.3 Key Financial Summary
12.18 Alvogen
12.18.1 Business Overview
12.18.2 Product and Service Offerings
12.19 Nichi-Iko Pharmaceutical Co. Ltd.
12.19.1 Business Overview
12.19.2 Product and Service Offerings
12.19.3 Key Financial Summary
12.20 Glenmark Life Sciences Limited
12.20.1 Business Overview
12.20.2 Product and Service Offerings
12.20.3 Key Financial Summary
12.21 Amphastar Pharmaceuticals Inc.
12.21.1 Business Overview
12.21.2 Product and Service Offerings
12.21.3 Key Financial Summary
12.22 MSN Labs
12.22.1 Business Overview
12.22.2 Product and Service Offerings
12.23 CUSTOPHARM INC.
12.23.1 Business Overview
12.23.2 Product and Service Offerings
12.24 Cadila Healthcare Ltd.
12.24.1 Business overview
12.24.2 Product and Service Offerings
12.24.3 Key Financial Summary
12.25 Pfizer Inc.
12.25.1 Business Overview
12.25.2 Product and Service Offerings
12.25.3 Key Financial Summary
12.26 Sanofi
12.26.1 Business Overview
12.26.2 Product and Service Offerings
12.26.3 Key Financial Summary
12.27 Bausch Health Companies Inc.
12.27.1 Business Overview
12.27.2 Product and Service Offerings
12.27.3 Key Financial Summary
Chapter 13. Appendix
13.1 Abbreviations
13.2 Sources and References
13.3 Related Reports
LIST OF TABLES
TABLE 1 VALUE MARKET SIZE ANALYSIS PERIOD
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)
TABLE 5 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)
TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)
TABLE 7 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)
TABLE 8 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)
TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)
TABLE 10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)
TABLE 11 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)
TABLE 12 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014–2019)
TABLE 13 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2020–2030)
TABLE 14 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)
TABLE 15 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)
TABLE 16 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)
TABLE 17 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)
TABLE 18 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)
TABLE 19 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)
TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)
TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)
TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)
TABLE 23 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)
TABLE 24 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)
TABLE 25 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)
TABLE 26 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)
TABLE 27 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)
TABLE 28 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)
TABLE 29 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)
TABLE 30 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)
TABLE 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)
TABLE 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)
TABLE 33 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)
TABLE 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)
TABLE 35 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)
TABLE 36 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)
TABLE 37 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)
TABLE 38 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)
TABLE 39 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)
TABLE 40 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)
TABLE 41 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)
TABLE 42 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)
TABLE 43 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)
TABLE 44 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)
TABLE 45 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)
TABLE 46 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)
TABLE 47 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)
TABLE 48 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)
TABLE 49 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)
TABLE 50 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)
TABLE 51 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)
TABLE 52 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)
TABLE 53 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)
TABLE 54 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)
TABLE 55 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)
TABLE 56 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)
TABLE 57 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)
TABLE 58 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)
TABLE 59 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)
TABLE 60 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)
TABLE 61 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)
TABLE 62 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)
TABLE 63 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)
TABLE 64 MAJOR PLAYERS AND THEIR OFFERINGS
TABLE 65 CIPLA LTD. – AT A GLANCE
TABLE 66 CIPLA LTD. – KEY FINANCIAL SUMMARY
TABLE 67 DR. REDDY’S LABORATORIES LTD. – AT A GLANCE
TABLE 68 DR. REDDY’S LABORATORIES LTD. – KEY FINANCIAL SUMMARY
TABLE 69 ALKEM LABORATORIES LIMITED – AT A GLANCE
TABLE 70 ALKEM LABORATORIES LIMITED – KEY FINANCIAL SUMMARY
TABLE 71 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – AT A GLANCE
TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – KEY FINANCIAL SUMMARY
TABLE 73 MYLAN N.V. – AT A GLANCE
TABLE 74 MYLAN N.V. – KEY FINANCIAL SUMMARY
TABLE 75 LUPIN LIMITED – AT A GLANCE
TABLE 76 LUPIN LIMITED – KEY FINANCIAL SUMMARY
TABLE 77 ENDO INTERNATIONAL PLC – AT A GLANCE
TABLE 78 ENDO INTERNATIONAL PLC – KEY FINANCIAL SUMMARY
TABLE 79 AUROBINDO PHARMA LIMITED – AT A GLANCE
TABLE 80 AUROBINDO PHARMA LIMITED – KEY FINANCIAL SUMMARY
TABLE 81 STADA ARZNEIMITTEL AG – AT A GLANCE
TABLE 82 STADA ARZNEIMITTEL AG – KEY FINANCIAL SUMMARY
TABLE 83 HIKMA PHARMACEUTICALS PLC – AT A GLANCE
TABLE 84 HIKMA PHARMACEUTICALS PLC – KEY FINANCIAL SUMMARY
TABLE 85 SAWAI PHARMACEUTICAL CO. LTD. – AT A GLANCE
TABLE 86 SAWAI PHARMACEUTICAL CO. LTD. – KEY FINANCIAL SUMMARY
TABLE 87 PIRAMAL ENTERPRISES LTD. – AT A GLANCE
TABLE 88 PIRAMAL ENTERPRISES LTD. – KEY FINANCIAL SUMMARY
TABLE 89 MALLINCKRODT PLC – AT A GLANCE
TABLE 90 MALLINCKRODT PLC – KEY FINANCIAL SUMMARY
TABLE 91 TORRENT PHARMACEUTICALS LTD. – AT A GLANCE
TABLE 92 TORRENT PHARMACEUTICALS LTD. – KEY FINANCIAL SUMMARY
TABLE 93 AMNEAL PHARMACEUTICALS INC. – AT A GLANCE
TABLE 94 AMNEAL PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY
TABLE 95 TARO PHARMACEUTICAL INDUSTRIES LTD. – AT A GLANCE
TABLE 96 TARO PHARMACEUTICAL INDUSTRIES LTD. – KEY FINANCIAL SUMMARY
TABLE 97 PERRIGO COMPANY PLC – AT A GLANCE
TABLE 98 PERRIGO COMPANY PLC – KEY FINANCIAL SUMMARY
TABLE 99 ALVOGEN – AT A GLANCE
TABLE 100 NICHI-IKO PHARMACEUTICAL CO. LTD. – AT A GLANCE
TABLE 101 NICHI-IKO PHARMACEUTICAL CO. LTD. – KEY FINANCIAL SUMMARY
TABLE 102 GLENMARK LIFE SCIENCES LIMITED – AT A GLANCE
TABLE 103 GLENMARK LIFE SCIENCES LIMITED – KEY FINANCIAL SUMMARY
TABLE 104 AMPHASTAR PHARMACEUTICALS INC. – AT A GLANCE
TABLE 105 AMPHASTAR PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY
TABLE 106 MSN LABS – AT A GLANCE
TABLE 107 CUSTOPHARM INC. – AT A GLANCE
TABLE 108 CADILA HEALTHCARE LTD. – AT A GLANCE
TABLE 109 CADILA HEALTHCARE LTD. – KEY FINANCIAL SUMMARY
TABLE 110 PFIZER INC. – AT A GLANCE
TABLE 111 PFIZER INC. – KEY FINANCIAL SUMMARY
TABLE 112 SANOFI – AT A GLANCE
TABLE 113 SANOFI – KEY FINANCIAL SUMMARY
TABLE 114 BAUSCH HEALTH COMPANIES INC. – AT A GLANCE
TABLE 115 BAUSCH HEALTH COMPANIES INC. – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 RESEARCH SCOPE
FIG 2 RESEARCH METHODOLOGY
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 6 DATA TRIANGULATION APPROACH
FIG 7 CURRENCY CONVERSION RATES FOR USD (2019)
FIG 8 GLOBAL GENERIC DRUGS MARKET SUMMARY
FIG 9 BARGAINING POWER OF BUYERS
FIG 10 BARGAINING POWER OF SUPPLIERS
FIG 11 INTENSITY OF RIVALRY
FIG 12 THREAT OF NEW ENTRANTS
FIG 13 THREAT OF SUBSTITUTES
FIG 14 SNAPSHOT OF GLOBAL GENERIC DRUGS MARKET
FIG 15 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)
FIG 16 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)
FIG 17 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)
FIG 18 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)
FIG 19 WORLDWIDE MAJOR MARKETS FOR GENERIC DRUGS
FIG 20 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014–2030)
FIG 21 NORTH AMERICA GENERIC DRUGS MARKET SNAPSHOT
FIG 22 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)
FIG 23 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)
FIG 24 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)
FIG 25 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)
FIG 26 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)
FIG 27 EUROPE GENERIC DRUGS MARKET SNAPSHOT
FIG 28 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)
FIG 29 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)
FIG 30 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)
FIG 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)
FIG 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)
FIG 33 APAC GENERIC DRUGS MARKET SNAPSHOT
FIG 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)
FIG 35 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)
FIG 36 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)
FIG 37 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)
FIG 38 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)
FIG 39 LATAM GENERIC DRUGS MARKET SNAPSHOT
FIG 40 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)
FIG 41 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)
FIG 42 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)
FIG 43 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)
FIG 44 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)
FIG 45 MEA GENERIC DRUGS MARKET SNAPSHOT
FIG 46 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)
FIG 47 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)
FIG 48 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)
FIG 49 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)
FIG 50 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)
FIG 51 CIPLA LTD. – REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2019)
FIG 52 DR. REDDY’S LABORATORIES LTD. – REVENUE SPLIT BY BUSSINESS SEGMENT AND GEOGRAPHY (2019)
FIG 53 ALKEM LABORATORIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2019)
FIG 54 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2019)
FIG 55 MYLAN N.V. – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2019)
FIG 56 LUPIN LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
FIG 57 ENDO INTERNATIONAL PLC – REVENUE SPLIT BY DIVISION (2019)
FIG 58 AUROBINDO PHARMA LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 59 STADA ARZNEIMITTEL AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 60 HIKMA PHARMACEUTICALS PLC – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)
FIG 61 SAWAI PHARMACEUTICAL CO. LTD. – REVENUE SPLIT BY GEOGRAPHY (2019)
FIG 62 PIRAMAL ENTERPRISES LTD. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)
FIG 63 MALLINCKRODT PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 64 TORRENT PHARMACEUTICALS LTD. – REVENUE SPLIT BY GEOGRAPHY (2019)
FIG 65 AMNEAL PHARMACEUTICALS INC. – REVENUE SPLIT BY SEGMENT (2019)
FIG 66 TARO PHARMACEUTICAL INDUSTRIES LTD. – REVENUE SPLIT BY GEOGRAPHY (2020)
FIG 67 PERRIGO COMPANY PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 68 NICHI-IKO PHARMACEUTICAL CO. LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 69 GLENMARK LIFE SCIENCES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2019)
FIG 70 AMPHASTAR PHARMACEUTICALS INC. – REVENUE SPLIT BY GEOGRAPHY (2019)
FIG 71 CADILA HEALTHCARE LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 72 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 73 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
FIG 74 BAUSCH HEALTH COMPANIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws